Frequently asked questions
Why does only Sunrise pass for Hims & Hers?
Because demand is the one part of the story with no counter-argument: cash-pay consumer health keeps expanding, GLP-1 policy (MFN pricing, TrumpRx, the Medicare bridge) enlarges the treated population, and peptides plus international add new dawns on the same infrastructure. Every other pillar carries a documented debit: leadership's regulatory escalations and insider selling, a moat rented from Novo in the largest category, a balance sheet with real obligations, and free cash flow that has not caught adjusted EBITDA.
Why is the Hims & Hers moat only a partial?
The owned layers are real: the category's defining brand buying at a falling share of revenue, five-plus specialties on one account, vertical integration across pharmacies, a peptide plant, and labs, and a nine-market international footprint. But in weight loss, the largest category, Hims now distributes Novo Nordisk's products at Novo's prices under a settlement that preserves Novo's right to refile its patent suit, while Lilly refuses supply entirely and manufacturer-direct channels cap any intermediary's take rate.
Why is Free Cash Flow only a partial despite $318M of adjusted EBITDA?
Conversion. Fiscal 2025's $318M of adjusted EBITDA became $57M of free cash flow after $135M of stock-based compensation and working capital, and H1 2026 free cash flow was negative as branded working capital, restructuring, and deal costs absorbed the recovery. The upgrade trigger is explicit in the analysis: two consecutive quarters of positive free cash flow at a gross margin of 65% or better.
Why does Sunrise pass?
Cash-pay consumer health expands as care shifts to asynchronous, condition-specific channels; GLP-1 adoption is being normalized by policy rather than restricted ($245/month public-program pricing, TrumpRx near $350, a Medicare bridge at $50 copays from July 2026, a $274 CMS-negotiated semaglutide price for 2027); at-home diagnostics, hormonal health, and peptides (July 2026 advisory vote in favor of six compounds) stack new categories on the same infrastructure; and ZAVA plus Eucalyptus move the model into earlier-stage international markets.
Why is Leadership a partial?
The creation half is elite: the category's defining brand, subscribers from ~290K to 2.89M, five specialties compounding at once, structured international deals, and a settlement extracted from weakness when the GLP-1 war reached an injunction suit. The calibration half is expensive: the $49 compounded pill launched into an announced FDA crackdown and died in 48 hours with a DOJ referral attached; the FTC's July 2026 suit alleges operating-culture failures; and insiders led by the CEO have sold persistently (roughly 7.5M shares, ~$191M since 2021 by secondary tallies, minimal buying). PARTIAL until the regulatory docket stays quiet for a year.
Why is Iron Fortress a partial?
Over $840M of cash and short-term investments, a $175M revolver, and a $400M receivables facility face $1.0B of converts due 2030 and $350M due 2032, plus up to ~$900M of Eucalyptus deferred and earnout consideration through early 2029, partly stock-settleable at the company's choice. No maturity lands before 2029, which protects the company; an unquantified FTC remedy and an open DOJ referral cap the grade. Time is the fortress here.
What would change the grades?
Leadership upgrades if the FTC file closes without structural remedies and insider selling pauses through 2027, and downgrades to FAIL on a DOJ filing. Moat upgrades if the Novo relationship renews on equal or better terms while peptide and international mix reduce weight-loss dependence. Iron Fortress upgrades if earnouts settle mostly in cash from operating flow. Free Cash Flow upgrades on two consecutive positive-FCF quarters at a 65%+ gross margin.
© 2026 DalalBytes Research · For educational purposes only. Not investment advice.